Ⓐ
PeptiBrief
Open label extension· 2019

Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire Disorder

Simon JA, Kingsberg SA, Shumel B, et al.

Obstetrics & Gynecology

PubMed
31599847
Evidence level
moderate
Verification
verified

Summary

A 52-week extension evaluating longer-term safety and persistence of effect.

Limitations

Open-label extension; selected participants may differ from non-completers.

Linked peptides

Important PeptiBrief is an educational information platform. It does not diagnose, prescribe, sell peptides, recommend dosing, encourage self-experimentation or replace qualified medical care. Published scientific evidence is kept separate from community observations and uncertainty.